Download presentation
Presentation is loading. Please wait.
Published byElijah Boyd Modified over 5 years ago
1
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert, MD, Anne Pradines, PhD, Anne Casanova, MS, Magali Farella, MS, Laura Keller, PhD, Jean-Charles Soria, MD, PhD, Gilles Favre, PhD, Julien Mazières, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 9, Pages e109-e112 (September 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Variations in the ratio of B-Raf proto-oncogene, serine/threonine kinase gene (BRAF)-mutated over wild-type (WT) circulating free DNA during treatment with dabrafenib (a B-Raf proto-oncogene, serine/threonine kinase inhibitor [BRAFi]) and trametinib (a mitogen-activated protein kinase inhibitor [MEKi]) in patient 1 and the correlations with a computed tomography scan. Journal of Thoracic Oncology , e109-e112DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 The increase in B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) V600E–mutated circulating tumor-specific DNA in patient 2 during treatment with vemurafenib concomitant with dramatic disease progression, as seen on a computed tomography scan. The BRAF V600E probe plot is shown. The pink line is the threshold for positive versus negative droplets. Journal of Thoracic Oncology , e109-e112DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.